Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Scientists develop new version of medication to relieve severe forms of pain

Scientists develop new version of medication to relieve severe forms of pain

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

Competitive Technologies anticipates $1M revenue from sales of Calmare Pain Therapy Treatment

Competitive Technologies anticipates $1M revenue from sales of Calmare Pain Therapy Treatment

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

Study highlights importance of individualized, patient-centered therapies

Study highlights importance of individualized, patient-centered therapies

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Pfizer announces suspension of osteoarthritis clinical program for tanezumab

Pfizer announces suspension of osteoarthritis clinical program for tanezumab

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

CTT's Calmare Pain Therapy Treatment shows promise against CIPN

CTT's Calmare Pain Therapy Treatment shows promise against CIPN

Pharnext closes €4.8-million Series A funding round

Pharnext closes €4.8-million Series A funding round

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Millennium announces data on VELCADE in treatment of patients with amyloidosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.